MAPK
Catalog No.
Product Name
Application
Product Information
Citations
-
p38α Inhibitor
FS-694 is a potent inhibitor of p38α, exhibiting an IC50 of 0.2 nM. This compound effectively suppresses TNFα release in human whole blood, with an IC50 value of 35.0 nM. FS-694 can be utilized in research aimed at understanding p38α signaling pathways and investigating inflammatory responses. -
p38 MAP Kinase Inhibitor
SC-68376 is a selective, reversible inhibitor of p38 MAP kinase, functioning through competitive inhibition of ATP binding. This compound exhibits significant biological activity in modulating inflammatory responses and cellular stress signaling pathways. SC-68376 is valuable for research applications related to inflammation, neurodegenerative diseases, and cancer, enabling the exploration of p38 MAP kinase's role in various pathological conditions. -
p38-α MAPK Inhibitor
p38-α MAPK-IN-9 is a highly potent inhibitor of the p38-α mitogen-activated protein kinase (MAPK), exhibiting a Ki value of 0.057 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNFα) production in human peripheral blood mononuclear cells (hPBMCs), with an IC50 of 18 nM. p38-α MAPK-IN-9 is valuable for research applications focused on inflammatory signaling pathways and the study of cytokine modulation. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor VI is a selective inhibitor of p38 MAPK, exhibiting a moderate inhibition rate of 24%. This compound is instrumental in research focused on inflammation, apoptosis, and cellular stress responses. It can be utilized to explore the role of p38 MAPK in various pathological conditions and to develop therapeutic strategies targeting this signaling pathway. -
p38 Inhibitor
p38 MAP Kinase-IN-1 is a selective inhibitor of the p38 MAP kinase pathway, which plays a crucial role in mediating inflammation and immune responses. This compound is valuable for researchers investigating the mechanisms behind inflammatory diseases and autoimmune disorders. It can facilitate studies aimed at understanding p38's role in cellular signaling and its potential as a therapeutic target in inflammatory-related conditions. -
p38 MAPK Inhibitor
p38 MAPK-IN-6 is a selective p38 MAPK inhibitor that exhibits potential in modulating inflammatory pathways and stress responses. With a demonstrated inhibitory effect of 14% at a concentration of 10 μM, this compound serves as a valuable tool for studying p38 MAPK signaling in various cellular models. Its application extends to research in conditions associated with chronic inflammation and related diseases. -
p38 MAPK Inhibitor
AKP-001 is a selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). This compound effectively reduces the production of pro-inflammatory cytokines, making it valuable for studying inflammatory processes. AKP-001 is particularly relevant for research focused on rheumatoid arthritis and inflammatory bowel disease, providing insights into potential therapeutic interventions for these conditions. -
p38 MAPK Inhibitor, coumarin, glucoside
Esculin sesquihydrate is a coumarin glucoside that serves as an inhibitor of p38 MAPK. This compound has demonstrated significant biological activity in ameliorating cognitive impairment associated with experimental diabetic nephropathy. Additionally, esculin sesquihydrate exhibits antioxidant and anti-inflammatory properties, primarily through modulation of the MAPK signaling pathway, making it valuable for research in diabetes-related complications and inflammation studies. -
p38α/β Degrader
NR-7h is a selective degrader of p38α and p38β, exhibiting DC50 values of 24 nM and 27.2 nM for p38α in T47D and MB-MDA-231 cells, respectively. This compound effectively induces degradation of these kinases, facilitating the study of their roles in cellular signaling pathways. NR-7h is applicable in cancer research and other studies investigating inflammatory responses and signal transduction mechanisms. -
p38 MAPK Inhibitor
PF-03715455 is a selective p38 MAPK inhibitor with significant potency, demonstrating IC50 values of 0.88 nM for p38α and 23 nM for p38β. This compound effectively inhibits LPS-induced TNFα production in human whole blood, with an IC50 of 1.7 nM. PF-03715455 has potential applications in research focusing on chronic obstructive pulmonary disease (COPD) and inflammation-related pathways. -
DDR/p38 Inhibitor
SR-302 is a selective DDR/p38 inhibitor that exhibits potent biological activity with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. This compound is valuable for investigating fibrotic disorders, including renal and pulmonary fibrosis, atherosclerosis, and various types of cancer. SR-302 serves as a key tool for elucidating the roles of DDR and p38 signaling pathways in disease progression and therapeutic intervention. -
p38/MAPK Inhibitor
LX-3 is a selective inhibitor of the p38 MAPK signaling pathway. It effectively modulates gene expression by reactivating silenced EGFP reporter genes associated with DNA methylation, including TNF, EGR1, LY6K, and ISG20. This reagent is valuable for studies investigating the roles of p38 MAPK in cellular processes and the impact of DNA methylation on gene regulation. -
p38 Inhibitor
p38α inhibitor 5 is a PROTAC-type ligand that specifically targets p38α MAP kinase. This compound is designed to facilitate the degradation of p38α, providing a valuable tool for studying the enzyme's role in cellular signaling and inflammation. It is suitable for applications in drug discovery and therapeutic research, particularly in the context of conditions associated with p38α dysregulation. -
p38 Inhibitor
Org 48762-0 is a selective p38 inhibitor, exhibiting a potent EC50 of 0.1 μM for p38α kinase. This compound demonstrates a high degree of specificity for both p38α and p38β over other kinases, allowing for targeted therapeutic interventions. Org 48762-0 effectively reduces lipopolysaccharide-induced TNFα release, making it a valuable tool in the study of inflammatory diseases. Its applications extend to researching conditions such as rheumatoid arthritis and Werner syndrome. -
p38α Inhibitor
Cyclocurcumin is a potent inhibitor of p38α, a key signaling molecule involved in inflammatory responses. It demonstrates significant antirheumatic, antivasoconstrictive, and antioxidant activities. This compound is valuable for research applications focused on inflammation, cardiovascular diseases, and oxidative stress. -
TAK1/p38α Inhibitor
PF-05381941 is a potent dual inhibitor of TAK1 and p38α, exhibiting IC50 values of 156 nM and 186 nM, respectively. This compound effectively modulates the MAPK signaling pathway, making it a valuable tool for investigating cellular responses to stress and inflammation. PF-05381941 is commonly utilized in research focused on cancer, autoimmune diseases, and other pathological conditions linked to dysregulated kinase activity. -
p38 MAPK Inhibitor
RO3201195 is a selective inhibitor of p38 MAPK, a key signaling molecule involved in inflammatory responses and cellular stress. This compound demonstrates potent inhibition of WS cell proliferation, with an IC50 value of 190 nM. RO3201195 is suitable for research applications aimed at understanding the role of p38 MAPK in various biological processes, including inflammation and cancer. -
BRD 4/p38α/BRDT Inhibitor
SB-284851-BT is a selective inhibitor of BRD4, p38α, and BRDT. It effectively inhibits BRD4-BD1 with an IC50 of 1.7 µM, p38α with a Kd of 0.47 nM, and exhibits additional inhibitory activity against BRDT and BRD4 with IC50 values of 18 µM and 3.7 µM, respectively. SB-284851-BT significantly reduces IL-8 production through p38α inhibition and downregulates crucial oncogenic pathways such as c-Myc and NF-κB via BRD4 inhibition. This compound has potential applications in cancer research and therapeutic development targeting cellular signaling pathways. -
JNK Inhibitor
JNK-IN-26 is a potent inhibitor of c-Jun N-terminal kinase (JNK), a key signaling enzyme involved in various cellular processes such as apoptosis, inflammation, and stress response. This compound exhibits significant biological activity by selectively inhibiting JNK signaling pathways, making it a valuable tool for studying JNK-related mechanisms in cellular and molecular biology. JNK-IN-26 is utilized in research applications focused on cancer, neurodegenerative diseases, and other conditions involving JNK activation. -
CDK/GSK3β/JNK Inhibitor
Indirubin-3′-oxime (IDR3O) is a synthetic derivative of indirubin that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), glycogen synthase kinase 3β (GSK3β), and all three isoforms of c-Jun N-terminal kinases (JNK1, JNK2, JNK3). It demonstrates inhibitory activity with IC50 values of 0.8 μM, 1.4 μM, and 1.0 μM for each JNK isoform, respectively. Indirubin-3′-oxime is also known to promote chondrocyte height growth through the activation of Wnt/β-catenin signaling, making it relevant for studies in cellular growth and differentiation. -
JNK Inhibitor
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3), exhibiting an IC50 value of 40 nM and a remarkable 2500-fold selectivity over JNK1α1 and JNK2α2 isoforms. This compound demonstrates significant neuroprotective activity in vitro, making it a valuable tool for researching neurodegenerative diseases and their therapeutic interventions. -
JNK Activator
CMX-8933 is a JNK activator derived from an octapeptide fragment of the goldfish brain neurotrophic factor ependymin. This compound enhances the enzymatic activity of c-Jun N-terminal kinase (JNK), leading to increased phosphorylation of JNK and c-Jun proteins, as well as elevated cellular levels of c-Jun and c-Fos mRNA. CMX-8933 serves as a valuable tool for investigating the roles of ependymin in neuroplasticity, learning processes, memory formation, and neural regeneration. -
JNK Inhibitor
SR-3306 is a selective pan-JNK (JNK1/2/3) inhibitor with notable brain-penetrating properties. It serves as a neuroprotective agent, making it valuable for investigating neurodegenerative diseases such as Parkinson's disease, as well as conditions related to ischemia/reperfusion (I/R) injury and obesity. Its targeted inhibition of JNK pathways offers potential insights into therapeutic strategies for these disorders. -
JNK3 Inhibitor
JNK3 inhibitor-4 is a selective inhibitor targeting JNK3 (IC50 = 1.0 nM), derived from a 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile scaffold. It demonstrates remarkable selectivity over JNK1 (IC50 = 143.9 nM) and JNK2 (IC50 = 298.2 nM). This compound exhibits neuroprotective properties and shows potential for effective delivery across the blood-brain barrier, making it valuable for research in neurodegenerative diseases and other neurological disorders. -
JNK Inhibitor
JNK3 inhibitor-1 is a potent and selective inhibitor of c-Jun N-terminal kinase 3 (JNK3), exhibiting an IC50 of 0.005 μM. It demonstrates oral bioavailability and the ability to penetrate the blood-brain barrier, making it suitable for neurological research. JNK3 inhibitor-1 is utilized in studies investigating the role of JNK3 in neurodegenerative disorders and various cellular processes. -
JNK1 Inhibitor
JNK-1-IN-3 is a selective inhibitor of JNK1 that effectively downregulates JNK1 gene expression and decreases the levels of its phosphorylated form. This compound concurrently reduces the expression of key downstream targets, including c-Jun and c-Fos, while enhancing p53 activity. JNK-1-IN-3 demonstrates significant antiproliferative effects, especially against renal and breast cancer cell lines, showcasing both in vitro and in vivo anticancer activity, making it a valuable tool for cancer research and therapeutic investigations. -
JNK Inhibitor
JNK-IN-11 is a selective JNK inhibitor, exhibiting IC50 values of 2.2 µM, 21.4 µM, and 1.8 µM for JNK1, JNK2, and JNK3, respectively. This compound demonstrates significant potential in research applications targeting neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, by modulating pathways involved in cell stress and apoptosis. JNK-IN-11 serves as a valuable tool for investigating therapeutic strategies in these conditions. -
JNK Inhibitor
JNK-IN-13 is a selective inhibitor of the c-Jun N-terminal kinases (JNK), demonstrating IC50 values of 290 nM for JNK3 and 500 nM for JNK2. This compound exhibits significant biological activity in modulating cellular stress responses, apoptosis, and inflammation pathways. JNK-IN-13 is valuable for research applications focused on cancer, neurodegenerative diseases, and metabolic disorders, providing insights into JNK signaling mechanisms. -
JNK Inhibitor
Salicortin is a phenolic glycoside that functions as a JNK inhibitor. It effectively inhibits osteoclast differentiation and bone resorption by down-regulating the JNK and NF-κB/NFATc1 signaling pathways. Salicortin exhibits a range of biological activities, including anti-amnesic, anti-adipogenic, and immune-modulatory effects, making it a valuable tool for research in bone metabolism, neurobiology, and immunology. -
JNK/CYP Inhibitor
JNK-IN-14 is a potent inhibitor of the c-Jun N-terminal kinase (JNK) family, demonstrating IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3. This compound effectively induces early apoptosis and causes cell cycle arrest in the G2/M phase. Additionally, JNK-IN-14 exhibits a modest inhibition of beclin-1 expression in K562 leukemia cells, indicating its potential application in cancer research and therapeutic strategies targeting JNK signaling pathways. -
JNKs Inhibitor
(-)-Zuonin A is a selective inhibitor of c-Jun N-terminal kinases (JNKs), demonstrating IC50 values of 1.7 μM, 2.9 μM, and 1.74 μM for JNK1, JNK2, and JNK3, respectively. As a naturally occurring lignin, it exhibits potent inhibitory activity, making it a valuable reagent for studies investigating JNK signaling pathways. This compound is applicable in research areas including cancer biology, neuroprotection, and inflammation. -
JNK1 Inhibitor
JNK-1-IN-5 is a selective JNK1 inhibitor exhibiting sub-nanomolar activity. This compound effectively suppresses TGF-β-induced epithelial-mesenchymal transition, making it a valuable tool in research focused on pulmonary fibrosis. JNK-1-IN-5 provides a promising avenue for investigating the role of JNK1 in fibrogenic processes and related therapeutic interventions. -
JNK1 Inhibitor
JD123 is a selective inhibitor of JNK1, demonstrating ATP-competitive inhibition of p38-γ MAPK. It effectively reduces the activity of JNK1 and the expression of cJun (1-135), while exhibiting no inhibitory effects on ERK1, ERK2, or the other p38 MAPK isoforms (α, β, and δ). JD123 is primarily utilized in research applications focused on cell signaling pathways, apoptosis, and inflammatory responses. -
JNK Inhibitor
JNK-1-IN-1 is a potent inhibitor of c-Jun N-terminal kinase 1 (JNK-1), demonstrating additional inhibitory effects on MKK7 with an IC50 of 7.8 μM. This compound selectively targets the JNK signaling pathway, which is crucial in regulating various cellular processes such as apoptosis, inflammation, and differentiation. JNK-1-IN-1 is valuable for research applications in cancer biology, neurodegenerative diseases, and inflammatory disorders, providing insights into the modulation of JNK-related signaling pathways. -
JNK-1 Inhibitor
JNK-IN-22 is a selective inhibitor of JNK-1, a key regulator in the stress-activated protein kinase signaling pathway. This compound demonstrates potent inhibition of JNK-1 activity, which is implicated in various cellular processes, including apoptosis, differentiation, and inflammation. JNK-IN-22 is utilized in research to explore its role in neurodegenerative diseases, cancer, and metabolic disorders, making it a valuable tool for understanding JNK-mediated signaling pathways. -
JNK1/2/3 Inhibitor
JNK-IN-25 is a highly selective inhibitor of JNK1, JNK2, and JNK3, exhibiting IC50 values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively. This compound acts by covalently binding to the conserved cysteine residue in the JNK isoforms, thereby obstructing the phosphorylation of c-Jun. JNK-IN-25 is valuable for investigating pathways involved in cancer, as well as in inflammatory and neurodegenerative diseases. -
JNK Inhibitor
CC-401 dihydrochloride is a potent inhibitor of c-Jun N-terminal kinases (JNK) with an inhibition constant (Ki) ranging from 25 to 50 nM. This compound effectively modulates JNK signaling pathways, making it valuable in studies related to cellular stress responses, apoptosis, and inflammatory processes. CC-401 dihydrochloride is applicable in various research areas, including cancer biology and neurodegenerative disease investigations. -
JNK-1 Inhibitor
JNK-IN-21 is a selective inhibitor of JNK-1, a member of the c-Jun N-terminal kinase family, which plays a crucial role in various cellular processes such as apoptosis and inflammation. By blocking JNK-1 activity, JNK-IN-21 demonstrates potential for modulating signaling pathways associated with stress responses and cellular differentiation. This compound is utilized in biological research to investigate JNK-related signaling mechanisms and their implications in disease models. -
JNK2 Inhibitor
JNK2-IN-1 is a selective inhibitor of JNK2, displaying a dissociation constant (Kd) of 79.2 μM. This compound exhibits anti-inflammatory properties by reducing the secretion of pro-inflammatory cytokines TNF-α and IL-6 through the inhibition of the NF-κB/MAPK signaling pathway. JNK2-IN-1 has demonstrated therapeutic potential in alleviating symptoms associated with LPS-induced acute lung injury (ALI) and sepsis, making it valuable for research in inflammation and related diseases. -
JNK Inhibitor
JNK-IN-23 is a potent inhibitor of c-Jun N-terminal kinases (JNK), demonstrating significant antiproliferative activity against MDA-MB-231 cells with a GIC50 of 30 nM. It effectively impedes metastatic growth in triple-negative breast cancer (TNBC) models in vivo, significantly reducing lung metastasis rates. JNK-IN-23 functions through the dual targeting of glutaminase-1 (GLS) and pyruvate dehydrogenase complex (PDHC), making it a valuable tool for research into cancer metabolism and metastasis. -
Inhibitor of the Phosphorylation of c-jun
TAT-JIP is an effective inhibitor of the phosphorylation of endogenous c-jun, particularly following activation by PHA-PMA. This compound is useful for studying the role of c-jun in various signaling pathways and cellular processes. Its application in research may extend to investigating the regulatory mechanisms involved in cell proliferation, differentiation, and response to stress. -
JNK3 Inhibitor
JNK3 Inhibitor-7 is a selective inhibitor of the c-Jun N-terminal kinase 3 (JNK3) pathway, exhibiting potent activity with IC50 values of 53 nM for JNK3, while demonstrating lesser inhibition against JNK2 and JNK1 at 973 nM and 1039 nM, respectively. This compound effectively crosses the blood-brain barrier and exhibits significant neuroprotective properties. JNK3 Inhibitor-7 holds potential for research applications related to neurodegenerative disorders, particularly Alzheimer's disease. -
p38 MAPK Activator
OVA-E1 peptide is an activator of p38 MAPK, derived from the original SIINFEKL sequence (OVA 257-264). This peptide effectively stimulates both p38 and JNK signaling pathways in both mutant and wild-type thymocytes. It serves as a valuable tool for studying MAPK pathways and their roles in cellular responses such as inflammation and stress signaling in various research applications. -
JNK Inhibitor
JNK-IN-24 is a selective inhibitor of c-Jun N-terminal kinase (JNK), demonstrating significant anti-metastatic properties in cancer research. By downregulating JNK and matrix metalloproteinase 1 (MMP1) expression in Scrib knockdown-induced cancer models, JNK-IN-24 facilitates recovery from tumorous phenotypes. This compound is suitable for investigations into a range of epithelial cell-derived cancers, contributing to the understanding of JNK's role in tumor progression and metastasis. -
c-Jun N-terminal Kinase Inhibitor
JNK-IN-19 is a selective inhibitor of c-Jun N-terminal kinase (JNK), an important regulator in cellular stress responses. This compound demonstrates significant biological activity by modulating pathways associated with apoptosis, inflammation, and cell survival. JNK-IN-19 shows potential utility in research focused on surgical interventions, neuroprotection, and conditions characterized by oxidative stress. It provides a valuable tool for investigating the role of JNK in various physiological and pathological processes. -
p38 MAPK Inhibitor, JNK Inhibitor
HE4-1 leech peptide is a selective inhibitor of p38 MAPK and c-Jun N-terminal kinase (JNK). It effectively suppresses macrophage migration while maintaining normal macrophage immunological functions, such as phagocytosis, lysozyme activity, and the expression of various inflammatory factors. This peptide is primarily utilized in research focused on atherosclerosis and inflammation-related studies. -
JNK3 Inhibitor
JNK3 Inhibitor-8 is a selective, orally bioavailable inhibitor targeting the c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 21 nM. It demonstrates pronounced neuroprotective effects and effectively crosses the blood-brain barrier. This compound is relevant for research applications related to neurodegenerative disorders, particularly Alzheimer’s disease. -
JNK3 Inhibitor
JNK3 Inhibitor-3 is a selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) that effectively permeates the blood-brain barrier and exhibits oral bioavailability. With IC50 values of 147.8 nM, 44.0 nM, and 4.1 nM for JNK1, JNK2, and JNK3 respectively, JNK3 Inhibitor-3 demonstrates significant inhibitory effects across these kinase targets. This compound has been shown to enhance memory performance in mouse models of dementia, making it a valuable tool for research in Alzheimer’s disease and related neurodegenerative disorders. -
JNK Inhibitor
JNK-1-IN-4 is a selective inhibitor of the c-Jun N-terminal kinase (JNK) family, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7 nM, 19.0 nM, and 9.0 nM, respectively. This compound effectively inhibits the phosphorylation of c-Jun and decreases the expression of TGF-β1-induced epithelial-to-mesenchymal transition (EMT) marker proteins, including fibronectin and α-SMA. JNK-1-IN-4 demonstrates favorable pharmacokinetic properties, evidenced by a bioavailability of 69%, and has shown anti-fibrotic effects in bleomycin-induced models of idiopathic pulmonary fibrosis. -
TOPK-p38/JNK Inhibitor
TOPK-p38/JNK-IN-1 is an orally active inhibitor targeting the TOPK-p38/JNK signaling pathway, exhibiting an IC50 value of 2.14 µM for nitric oxide production. This compound demonstrates significant anti-inflammatory activity by inhibiting the phosphorylation of downstream proteins while preventing degradation of TOPK. Research applications include studies on inflammatory processes and cellular signaling mechanisms in various disease models.
